Age, sex, and categorical markers values of the patients (cohort 1)
| . | CLL . | FL . | HCL . | LPL . | MCL . | MZL . |
|---|---|---|---|---|---|---|
| Number, % | 182 (37.9) | 11 (2.3) | 22 (4.6) | 107 (22.3) | 52 (10.8) | 106 (22.1) |
| Male-to-female ratio | 1.6 | 1.3 | 5.3 | 1.4 | 1.6 | 1.3 |
| Mean age, y | 71.9 | 64.6 | 61.4 | 73.2 | 68.9 | 75.7 |
| CD10+/CD10– | 1/181 | 10/1 | 2/20 | 3/104 | 0/52 | 2/104 |
| CD5+/CD5– | 170/12 | 1/10 | 1/21 | 19/88 | 45/7 | 12/94 |
| CD23+/CD23– | 171/11 | 7/4 | 3/19 | 29/78 | 14/38 | 20/86 |
| CD22/CD79b (low/medium to high) | 159/23 | 3/8 | 1/21 | 30/77 | 8/44 | 2/104 |
| Surface immunoglobulin light chains (low/medium to high) | 159/23 | 1/10 | 2/20 | 7/100 | 3/49 | 8/98 |
| FMC7+/FMC7– | 46/136 | 10/1 | 21/1 | 63/44 | 46/6 | 101/5 |
| . | CLL . | FL . | HCL . | LPL . | MCL . | MZL . |
|---|---|---|---|---|---|---|
| Number, % | 182 (37.9) | 11 (2.3) | 22 (4.6) | 107 (22.3) | 52 (10.8) | 106 (22.1) |
| Male-to-female ratio | 1.6 | 1.3 | 5.3 | 1.4 | 1.6 | 1.3 |
| Mean age, y | 71.9 | 64.6 | 61.4 | 73.2 | 68.9 | 75.7 |
| CD10+/CD10– | 1/181 | 10/1 | 2/20 | 3/104 | 0/52 | 2/104 |
| CD5+/CD5– | 170/12 | 1/10 | 1/21 | 19/88 | 45/7 | 12/94 |
| CD23+/CD23– | 171/11 | 7/4 | 3/19 | 29/78 | 14/38 | 20/86 |
| CD22/CD79b (low/medium to high) | 159/23 | 3/8 | 1/21 | 30/77 | 8/44 | 2/104 |
| Surface immunoglobulin light chains (low/medium to high) | 159/23 | 1/10 | 2/20 | 7/100 | 3/49 | 8/98 |
| FMC7+/FMC7– | 46/136 | 10/1 | 21/1 | 63/44 | 46/6 | 101/5 |
CLL, chronic lymphocytic leukemia.